IL321343A - Methods of treating multiple myeloma - Google Patents
Methods of treating multiple myelomaInfo
- Publication number
- IL321343A IL321343A IL321343A IL32134325A IL321343A IL 321343 A IL321343 A IL 321343A IL 321343 A IL321343 A IL 321343A IL 32134325 A IL32134325 A IL 32134325A IL 321343 A IL321343 A IL 321343A
- Authority
- IL
- Israel
- Prior art keywords
- concentration
- histidine
- present
- pharmaceutical formulation
- sucrose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797876P | 2019-01-28 | 2019-01-28 | |
| US201962847826P | 2019-05-14 | 2019-05-14 | |
| US201962861954P | 2019-06-14 | 2019-06-14 | |
| US201962899094P | 2019-09-11 | 2019-09-11 | |
| US201962931014P | 2019-11-05 | 2019-11-05 | |
| EP19306554 | 2019-12-03 | ||
| US201962943716P | 2019-12-04 | 2019-12-04 | |
| PCT/US2020/015455 WO2020160020A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321343A true IL321343A (en) | 2025-08-01 |
Family
ID=69646031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321343A IL321343A (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
| IL285110A IL285110B2 (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285110A IL285110B2 (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11939390B2 (https=) |
| EP (2) | EP3917961A1 (https=) |
| JP (2) | JP7712206B2 (https=) |
| KR (1) | KR20210120048A (https=) |
| CN (2) | CN120754030A (https=) |
| AU (1) | AU2020215692A1 (https=) |
| BR (1) | BR112021014699A2 (https=) |
| CA (1) | CA3127928A1 (https=) |
| CO (1) | CO2021011034A2 (https=) |
| IL (2) | IL321343A (https=) |
| MA (1) | MA54860A (https=) |
| MX (1) | MX2021009079A (https=) |
| SG (1) | SG11202108029XA (https=) |
| TW (2) | TW202535952A (https=) |
| WO (1) | WO2020160020A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| JP6730260B2 (ja) | 2014-09-12 | 2020-07-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | マクロピノサイトーシスによるヒト抗ｃｄ４６抗体及び標的とされた癌治療薬 |
| JP7712206B2 (ja) | 2019-01-28 | 2025-07-23 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置方法 |
| EP3969004A1 (en) * | 2019-05-14 | 2022-03-23 | Sanofi | Methods of administering anti-cd38 antibody to treat multiple myeloma |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| IL293563A (en) * | 2019-12-05 | 2022-08-01 | Sanofi Aventis Us Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| EP4192511A1 (en) * | 2020-08-07 | 2023-06-14 | Fortis Therapeutics, Inc. | Immunoconjugates targeting cd46 and methods of use thereof |
| IL302640A (en) * | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| US20240058464A1 (en) * | 2021-01-07 | 2024-02-22 | Fortis Therapeutics, Inc. | Combination therapy with for46 for cancer |
| CN114219787B (zh) * | 2021-12-17 | 2024-08-06 | 三峡大学 | 一种初诊多发性骨髓瘤预后分期系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| LT2882441T (lt) * | 2012-08-09 | 2020-07-27 | Celgene Corporation | Su imunitetu susijusių ir uždegiminių ligų gydymas |
| WO2016022589A2 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| HUE054271T2 (hu) * | 2015-05-13 | 2021-08-30 | Morphosys Ag | Mielóma Multiplex (MM) kezelése |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| IL256242B2 (en) * | 2015-06-22 | 2024-09-01 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| US20180153989A1 (en) * | 2016-12-02 | 2018-06-07 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| CA3069558A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| JP7712206B2 (ja) | 2019-01-28 | 2025-07-23 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置方法 |
-
2020
- 2020-01-28 JP JP2021543372A patent/JP7712206B2/ja active Active
- 2020-01-28 WO PCT/US2020/015455 patent/WO2020160020A1/en not_active Ceased
- 2020-01-28 IL IL321343A patent/IL321343A/en unknown
- 2020-01-28 CN CN202510783436.0A patent/CN120754030A/zh active Pending
- 2020-01-28 AU AU2020215692A patent/AU2020215692A1/en active Pending
- 2020-01-28 US US16/775,025 patent/US11939390B2/en active Active
- 2020-01-28 EP EP20706606.9A patent/EP3917961A1/en active Pending
- 2020-01-28 SG SG11202108029XA patent/SG11202108029XA/en unknown
- 2020-01-28 CA CA3127928A patent/CA3127928A1/en active Pending
- 2020-01-28 EP EP25172506.5A patent/EP4588484A3/en active Pending
- 2020-01-28 MX MX2021009079A patent/MX2021009079A/es unknown
- 2020-01-28 KR KR1020217027098A patent/KR20210120048A/ko active Pending
- 2020-01-28 BR BR112021014699A patent/BR112021014699A2/pt unknown
- 2020-01-28 MA MA054860A patent/MA54860A/fr unknown
- 2020-01-28 CN CN202080024773.7A patent/CN114026121A/zh active Pending
- 2020-01-28 IL IL285110A patent/IL285110B2/en unknown
- 2020-01-30 TW TW114114347A patent/TW202535952A/zh unknown
- 2020-01-30 TW TW109102902A patent/TWI904081B/zh active
-
2021
- 2021-08-23 CO CONC2021/0011034A patent/CO2021011034A2/es unknown
-
2024
- 2024-02-16 US US18/443,878 patent/US20240190984A1/en active Pending
-
2025
- 2025-07-09 JP JP2025115594A patent/JP2025148430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148430A (ja) | 2025-10-07 |
| BR112021014699A2 (pt) | 2021-11-23 |
| EP3917961A1 (en) | 2021-12-08 |
| CN120754030A (zh) | 2025-10-10 |
| TW202043283A (zh) | 2020-12-01 |
| CN114026121A (zh) | 2022-02-08 |
| US20200239589A1 (en) | 2020-07-30 |
| CA3127928A1 (en) | 2020-08-06 |
| IL285110B2 (en) | 2025-11-01 |
| AU2020215692A1 (en) | 2021-09-16 |
| MA54860A (fr) | 2022-05-04 |
| US20240190984A1 (en) | 2024-06-13 |
| SG11202108029XA (en) | 2021-08-30 |
| EP4588484A2 (en) | 2025-07-23 |
| TW202535952A (zh) | 2025-09-16 |
| WO2020160020A1 (en) | 2020-08-06 |
| IL285110B1 (en) | 2025-07-01 |
| IL285110A (en) | 2021-09-30 |
| MX2021009079A (es) | 2022-02-10 |
| TWI904081B (zh) | 2025-11-11 |
| JP7712206B2 (ja) | 2025-07-23 |
| US11939390B2 (en) | 2024-03-26 |
| EP4588484A3 (en) | 2025-10-15 |
| JP2022518060A (ja) | 2022-03-11 |
| CO2021011034A2 (es) | 2021-09-09 |
| KR20210120048A (ko) | 2021-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL321343A (en) | Methods of treating multiple myeloma | |
| US10265373B2 (en) | Pharmaceutical composition and method of treating a microbial infection with sulcotidil | |
| US8940723B2 (en) | Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine | |
| EP3810095A1 (en) | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor | |
| IL314009B2 (en) | Parp1 inhibitors and their uses | |
| US9789101B2 (en) | Methods and compositions for treating microbial infection using pyrroloquinone | |
| WO2019246312A9 (en) | Treatment of a disease of the gastrointestinal tract with an immunomodulator | |
| US9216186B2 (en) | Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent | |
| WO2020246750A3 (ko) | 안정화된 핵산 면역증강제를 함유하는 약학 조성물 | |
| JP2015536949A (ja) | 細菌感染症のための抗生物質を用いる方法および組成物 | |
| WO2023172641A3 (en) | Target substrate protein degradation platform | |
| ZA202203563B (en) | Pediatric suspension formulation | |
| Glupczynski | In vitro susceptibility testing of Helicobacter pylori to antimicrobial agents: basis for treatment or microbiologists' obsession? | |
| WO2018162928A1 (en) | Method for restoring efficacy of an antibacterial agent | |
| KR20150095282A (ko) | 안정화된 페니실린 복합 현탁 제제 | |
| US20060063837A1 (en) | Stabilized leukotriene B4 (LTB4) agent pharmaceutical formulation | |
| WO2025188658A8 (en) | Akt1 modulators | |
| IL312857A (en) | Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods | |
| WO2015016694A1 (es) | Composición sólida estable de inmunosupresores | |
| HK1183615A (en) | Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent | |
| HK1183615B (en) | Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent |